FI3692140T3 - Menetelmiä solujen laajentamiseksi selektiivisesti ekspressoiden TCR:ää vakiolla muriinialueella - Google Patents
Menetelmiä solujen laajentamiseksi selektiivisesti ekspressoiden TCR:ää vakiolla muriinialueella Download PDFInfo
- Publication number
- FI3692140T3 FI3692140T3 FIEP18786145.5T FI18786145T FI3692140T3 FI 3692140 T3 FI3692140 T3 FI 3692140T3 FI 18786145 T FI18786145 T FI 18786145T FI 3692140 T3 FI3692140 T3 FI 3692140T3
- Authority
- FI
- Finland
- Prior art keywords
- tcr
- cells
- human
- express
- constant region
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 19
- 241001529936 Murinae Species 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 11
- 210000004027 cell Anatomy 0.000 claims 10
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 230000021953 cytokinesis Effects 0.000 claims 3
- 230000000890 antigenic effect Effects 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- 108091033409 CRISPR Proteins 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- 238000010459 TALEN Methods 0.000 claims 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 claims 1
- 239000004234 Yellow 2G Substances 0.000 claims 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 238000004520 electroporation Methods 0.000 claims 1
- 108010074108 interleukin-21 Proteins 0.000 claims 1
- 239000002151 riboflavin Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000010361 transduction Methods 0.000 claims 1
- 230000026683 transduction Effects 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 230000009466 transformation Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
- A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4238—Regulators of development
- A61K40/424—Apoptosis related proteins, e.g. survivin or livin
- A61K40/4241—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
- A61K40/4272—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
- A61K2239/28—Expressing multiple CARs, TCRs or antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2301—Interleukin-1 (IL-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2312—Interleukin-12 (IL-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762568339P | 2017-10-05 | 2017-10-05 | |
| PCT/US2018/052432 WO2019070435A1 (en) | 2017-10-05 | 2018-09-24 | METHODS FOR SELECTIVE EXPANSION OF CELLS EXPRESSING A TCR WITH A CONSTANT MURINE REGION |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3692140T3 true FI3692140T3 (fi) | 2023-10-11 |
Family
ID=63841049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18786145.5T FI3692140T3 (fi) | 2017-10-05 | 2018-09-24 | Menetelmiä solujen laajentamiseksi selektiivisesti ekspressoiden TCR:ää vakiolla muriinialueella |
Country Status (13)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3786178A1 (en) | 2019-08-30 | 2021-03-03 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Tcr constructs specific for ebv-derived antigens |
| CA3202874A1 (en) * | 2020-12-22 | 2022-06-30 | Carsten LINNEMANN | Peptide markers to track genetically engineered cells |
| JP2024507929A (ja) | 2021-02-25 | 2024-02-21 | アラウノス セラピューティクス インコーポレイテッド | 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法 |
| WO2023150562A1 (en) | 2022-02-01 | 2023-08-10 | Alaunos Therapeutics, Inc. | Methods for activation and expansion of t cells |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993011794A1 (en) | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US6063983A (en) | 1995-09-05 | 2000-05-16 | The General Hospital Corporation | Monoclonal lymphocytes and methods of use |
| DE19905048A1 (de) | 1999-02-08 | 2000-08-10 | Gsf Forschungszentrum Umwelt | Verwendung depletorisch oder mitogen wirkender Antikörper in der Immuntherapie |
| JP2003274960A (ja) * | 2000-02-03 | 2003-09-30 | Japan Science & Technology Corp | 可溶性ｔ細胞受容体タンパク質およびその作成方法 |
| JP2003276960A (ja) * | 2002-03-26 | 2003-10-02 | Mitsubishi Electric Corp | エレベーター制御システム |
| US8034334B2 (en) | 2002-09-06 | 2011-10-11 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy |
| KR101131297B1 (ko) * | 2003-11-10 | 2012-03-30 | 알토 바이오사이언스 코포레이션 | 가용성 티씨알 분자 및 이용 방법 |
| US20090304657A1 (en) * | 2006-05-03 | 2009-12-10 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Chimeric t cell receptors and related materials and methods of use |
| CA2674445C (en) | 2007-01-12 | 2016-06-07 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Gp100-specific t cell receptors and related materials and methods of use |
| US8785601B2 (en) | 2009-01-28 | 2014-07-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors and related materials and methods of use |
| US8383099B2 (en) | 2009-08-28 | 2013-02-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Adoptive cell therapy with young T cells |
| US9345748B2 (en) | 2010-09-21 | 2016-05-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-SSX-2 T cell receptors and related materials and methods of use |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| ES2835200T3 (es) | 2012-05-22 | 2021-06-22 | Us Health | Uso médico de células que comprenden receptores de células T anti-NY-ESO-1 |
| US9879065B2 (en) * | 2012-09-14 | 2018-01-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing MHC class II-restricted MAGE-A3 |
| CN110511960B (zh) * | 2013-07-15 | 2023-05-23 | 美国卫生和人力服务部 | 抗人乳头瘤病毒16 e6 t细胞受体 |
| PT3149031T (pt) | 2014-05-29 | 2020-03-25 | Us Health | Receptores de células t anti-e7 do papilomavírus humano 16 |
| CN107075479A (zh) * | 2014-10-02 | 2017-08-18 | 美国卫生和人力服务部 | 分离对癌症特异性突变具有抗原特异性的t细胞的方法 |
| EP3220928B1 (en) * | 2014-11-20 | 2022-10-05 | UMC Utrecht Holding B.V. | A method of obtaining a preparation enrichmed in engineered t cells with exogenous immune receptors |
| SG10201913978RA (en) | 2014-11-26 | 2020-03-30 | The United States Of America As Represented By The Secretary | Anti-mutated kras t cell receptors |
| SG10201913868XA (en) | 2015-09-15 | 2020-03-30 | The United States Of America As Represented By The Secretary | T cell receptors recognizing hla-cw8 restricted mutated kras |
| DK3448882T3 (da) | 2016-04-26 | 2022-02-21 | Us Health | Anti-kk-lc-1-t-cellereceptorer |
| SG11201900654QA (en) | 2016-08-02 | 2019-02-27 | Us Health | Anti-kras-g12d t cell receptors |
-
2018
- 2018-09-24 US US16/652,948 patent/US12227554B2/en active Active
- 2018-09-24 WO PCT/US2018/052432 patent/WO2019070435A1/en not_active Ceased
- 2018-09-24 AU AU2018345400A patent/AU2018345400B2/en active Active
- 2018-09-24 JP JP2020519092A patent/JP7867764B2/ja active Active
- 2018-09-24 IL IL273698A patent/IL273698B2/en unknown
- 2018-09-24 FI FIEP18786145.5T patent/FI3692140T3/fi active
- 2018-09-24 CA CA3077595A patent/CA3077595A1/en active Pending
- 2018-09-24 KR KR1020207012314A patent/KR102757789B1/ko active Active
- 2018-09-24 ES ES18786145T patent/ES2960313T3/es active Active
- 2018-09-24 EP EP18786145.5A patent/EP3692140B1/en active Active
- 2018-09-24 SG SG11202003112QA patent/SG11202003112QA/en unknown
- 2018-09-24 CN CN201880076862.9A patent/CN111417720B/zh active Active
- 2018-09-24 EP EP23185846.5A patent/EP4269595A3/en active Pending
- 2018-09-24 MA MA050748A patent/MA50748A/fr unknown
-
2023
- 2023-12-26 JP JP2023220106A patent/JP7747724B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US12227554B2 (en) | 2025-02-18 |
| IL273698A (en) | 2020-05-31 |
| KR102757789B1 (ko) | 2025-01-20 |
| JP2024050551A (ja) | 2024-04-10 |
| EP4269595A3 (en) | 2023-12-06 |
| US20200254018A1 (en) | 2020-08-13 |
| WO2019070435A8 (en) | 2020-01-30 |
| JP7867764B2 (ja) | 2026-06-01 |
| JP7747724B2 (ja) | 2025-10-01 |
| KR20200064107A (ko) | 2020-06-05 |
| EP3692140B1 (en) | 2023-07-19 |
| AU2018345400A1 (en) | 2020-05-07 |
| WO2019070435A1 (en) | 2019-04-11 |
| SG11202003112QA (en) | 2020-05-28 |
| CN111417720A (zh) | 2020-07-14 |
| CA3077595A1 (en) | 2019-04-11 |
| IL273698B2 (en) | 2025-07-01 |
| IL273698B1 (en) | 2025-03-01 |
| EP4269595A2 (en) | 2023-11-01 |
| AU2018345400B2 (en) | 2024-06-20 |
| ES2960313T3 (es) | 2024-03-04 |
| JP2020535832A (ja) | 2020-12-10 |
| CN111417720B (zh) | 2025-02-07 |
| EP3692140A1 (en) | 2020-08-12 |
| MA50748A (fr) | 2020-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273698B2 (en) | Methods for selectively expanding cells expressing a tcr with a murine constant region | |
| MY200528A (en) | Gamma delta t cells and a method of augmenting the tumoricidal activity of the same | |
| NZ797963A (en) | Antibodies against pd-l1 | |
| EP3991578A3 (en) | Aerosol generation method and apparatus | |
| EP4644554A3 (en) | METHOD FOR TREATING AN AUTOIMMUNE DISEASE USING CD4 T LYMPHOCYTES WITH MODIFIED STABILIZATION OF ENDOGENOUS FOXP3 GENE EXPRESSION | |
| EP4309739A3 (en) | Core/shell structure platform for immunotherapy | |
| CR20200195A (es) | Proteínas de unión a antigenos de maduraciòn de celulas b | |
| EP4289944A3 (en) | Method for preparing genetically-modified t cells which express chimeric antigen receptor | |
| PH12018501335A1 (en) | Novel generation of antigen-specific tcrs | |
| AR109451A1 (es) | Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresión | |
| MX2021005021A (es) | Proceso para producir celulas t geneticamente modificadas. | |
| EP4043031A3 (en) | Zika viral antigen constructs | |
| WO2018161049A8 (en) | Compositions and methods for inducing hiv-1 antibodies | |
| WO2017152146A3 (en) | Compositions and methods for inducing hiv-1 antibodies | |
| IN2013CH04135A (cg-RX-API-DMAC10.html) | ||
| MX2018014554A (es) | Anticuerpo penetrante de citosol y uso del mismo. | |
| NZ789406A (en) | Engineered immune killer cell, preparation method therefor and use thereof | |
| JP2020535832A5 (cg-RX-API-DMAC10.html) | ||
| EP4557431A4 (en) | SOLID ELECTROLYTE, ITS MANUFACTURING PROCESS AND ALL-SOLID BATTERY INCLUDING IT | |
| MX2022005086A (es) | Anticuerpos anti-cd73 inmunomoduladores y usos de estos. | |
| TW200611706A (en) | Cytotoxic t lymphocyte | |
| EP4234686A3 (en) | Transduction and expansion of cells | |
| EP4248991A3 (en) | Methods and materials for expanding antigen-specific t cells in culture | |
| DE60226612D1 (de) | Autologe t-zell-vakzinmaterialien und verfahren | |
| MX2025003959A (es) | Materiales y metodos para expresion sin celulas de concatemeros de epitopos de vacuna |